As of 2026-06-13, the Relative Valuation of Denali Therapeutics Inc (DNLI) is (71.61) USD. This relative valuation is based on P/E multiples. With the latest stock price at 21.02 USD, the upside of Denali Therapeutics Inc based on Relative Valuation is -440.7%.
The range of the Relative Valuation is (69.43) - (69.76) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 21.5x - 24.5x | 23.0x |
| Forward P/E multiples | 21.1x - 21.6x | 21.4x |
| Fair Price | (69.43) - (69.76) | (71.61) |
| Upside | -430.3% - -431.9% | -440.7% |
| Date | P/E |
| 2026-06-10 | -6.57 |
| 2026-06-09 | -6.44 |
| 2026-06-08 | -6.05 |
| 2026-06-05 | -6.04 |
| 2026-06-04 | -6.24 |
| 2026-06-03 | -6.09 |
| 2026-06-02 | -5.99 |
| 2026-06-01 | -6.32 |
| 2026-05-29 | -6.52 |
| 2026-05-28 | -6.49 |
| 2026-05-27 | -6.26 |
| 2026-05-26 | -6.00 |
| 2026-05-22 | -5.77 |
| 2026-05-21 | -5.98 |
| 2026-05-20 | -5.83 |
| 2026-05-19 | -5.61 |
| 2026-05-18 | -5.70 |
| 2026-05-15 | -5.77 |
| 2026-05-14 | -6.00 |
| 2026-05-13 | -6.13 |
| 2026-05-12 | -6.03 |
| 2026-05-11 | -6.09 |
| 2026-05-08 | -6.08 |
| 2026-05-07 | -6.10 |
| 2026-05-06 | -6.32 |
| 2026-05-05 | -5.86 |
| 2026-05-04 | -5.78 |
| 2026-05-01 | -5.67 |
| 2026-04-30 | -5.80 |
| 2026-04-29 | -5.76 |
| 2026-04-28 | -6.21 |
| 2026-04-27 | -6.17 |
| 2026-04-24 | -6.15 |
| 2026-04-23 | -6.02 |
| 2026-04-22 | -6.27 |
| 2026-04-21 | -6.23 |
| 2026-04-20 | -6.36 |
| 2026-04-17 | -6.37 |
| 2026-04-16 | -6.41 |
| 2026-04-15 | -6.71 |
| 2026-04-14 | -6.24 |
| 2026-04-13 | -6.01 |
| 2026-04-10 | -5.95 |
| 2026-04-09 | -5.97 |
| 2026-04-08 | -6.08 |
| 2026-04-07 | -6.01 |
| 2026-04-06 | -6.00 |
| 2026-04-02 | -6.39 |
| 2026-04-01 | -6.09 |
| 2026-03-31 | -5.95 |